第1章 簡介

第2章 市場概要

市場定義和範圍

主要調查結果

指標分析

市場趨勢

競爭環境

波特五力分析模式

主要的購買標準

策略性建議

策略性結論

第3章 市場決策因素

推動市場的要素

阻礙市場的要素

市場機會

市場課題

親市場

競爭市場/替代市場

第4章 市場區隔

各腫瘤

各類型

各分析技術

各用途

第5章 各地區分析

北美

歐洲

亞太地區

其他

第6章 企業簡介

目錄

Product Code: HBI-1321015

The global cancer biomarker market is anticipated to witness an impressive growth rate of approx. 12% during the forecasted period 2016-2022. The global cancer biomarkers market can be segregated on the basis of tumor type including prostate cancer,cervical cancer, lung cancer, colorectal cancer, breast cancer and various other cancers. Breast cancer & prostate cancer were the largest disease indications included within the study in 2014. The market can further be bifurcated on the basis of biomarker type including protein biomarkers, genetic biomarkers and various other cancer biomarkers comprising viral, cell and carbohydrate biomarkers. Moreover, on the basis of applications, the market is segmented into risk assessment, prognostics, diagnostics, drug discovery & development and others. Among the numerous applications, diagnostics segment accounts for the major share in the global cancer biomarkers market owing to the increasing need for early stage diagnosis and rising demand for advanced diagnostics test. This application includes tests that access the biological makeup of patients at the molecular level to determine the predisposition of an individual to a specific disease or condition and diagnose it. The market can also be bifurcated on the basis of technologies comprising of immunoassays, imaging technologies, omics technologies, bioinformatics and cytogenetic. Among them, omics technologies hold the largest market share in 2014 owing to the increasing demand for tailor made treatment procedure and rising technological advancements. The cancer biomarker market is dominated by some major companies such as Abbott Laboratories, Qiagen NV, Becton Dickinson and Company, Roche Diagnostics Ltd. ,Illumina, Inc. and Thermo Fisher Scientific Inc.

The cancer biomarkers market is majorly driven by the rise in technological advancements coupled with increasing usage of cancer biomarkers in drug discovery & development. Increase in prevalence of cancer is the key driver that has attributed to a great extent towards the growth of the cancer biomarkers market. According to American Cancer Society, approximately 1,658,370 new cancer cases were diagnosed in 2015 in the US Moreover, this number is anticipated to increase to 1,685,210 by 2016. High growth in the prevalence has generated significant demand for the cancer biomarkers in the current times. Furthermore, the increasing awareness related to the usage of biomarkers at various stages of cancer along with the increasing consumption of tobacco has attributed towards the growth of the global cancer biomarkers market. Tobacco is one of the leading cause of cancer and has impacted significantly towards the increasing prevalence of cancer. In every 6 seconds, one person die from a tobacco related disease. Increasing demand for personalized medicine and rising demand for cancer biomarkers from the emerging economies is expected to offer potential growth opportunities for the global cancer biomarkers market.

The report segmented cancer biomarkers market on the basis of tumor type, technology, biomarker type, application and region. The country level analysis of each geographical region is the USP of our report. The analysis of the report is based on various parameters such as prevalence of cancer across geographies, adoption rate of cancer biomarkers in various applications and R&D investment by key market players. The data is collected through primary and secondary research. The report provides detailed analysis of key market players and their strategies.

Table of Contents

1. INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

2.1. MARKET DEFINITION AND SCOPE

2.2. KEY FINDINGS

2.3. PARAMETRIC ANALYSIS

2.4. KEY MARKET INSIGHTS

2.4.1. TOP EMERGING COUNTRIES

2.4.2. TOP REVENUE GENERATING SEGMENTS

2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS

2.4.4. TOP GEOGRAPHY

2.5. COMPETITIVE LANDSCAPE

2.5.1. MARKET SHARE ANALYSIS

2.5.2. TOP WINNING STRATEGIES

2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES

2.6. PORTER'S FIVE FORCE MODEL

2.6.1. THREAT OF NEW ENTRANTS

2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES

2.6.3. BARGAINING POWER OF BUYER

2.6.4. BARGAINING POWER OF SUPPLIER

2.6.5. INTENSITY OF COMPETITIVE RIVALRY

2.7. KEY BUYING CRITERIA

2.8. STRATEGIC RECOMMENDATION

2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1. RISING CANCER PREVALENCE

3.1.2. ENHANCED ACCURACY AND SPEED OF DIAGNOSIS

3.1.3. INCREASING RESEARCH ON CANCER BIOMARKERS

3.1.4. FDA SUPPORT FOR BIOMARKER DEVELOPMENT

3.2. MARKET RESTRAINTS

3.2.1. POOR REIMBURSEMENT SYSTEMS

3.2.2. HIGH CAPITAL INVESTMENT AND LOW BENEFIT-COST RATIO

3.2.3. TECHNICAL ISSUES OF SAMPLE COLLECTION AND STORAGE

3.3. MARKET OPPORTUNITIES

3.3.1. PERSONALIZED MEDICINE

3.3.2. COMPANION DIAGNOSTICS

3.3.3. EMERGING ECONOMIES

3.4. MARKET CHALLENGES

3.4.1. PROVING CLINICAL VALIDITY AND UTILITY OF BIOMARKER-BASED TESTS LEADING TO THEIR INSUFFICIENT ACCEPTANCE